- ISIN
- US2521311074
- CUSIP
- 252131107
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Apr 14, 2005
Highlights
- Market Cap
- $27.19B
- Enterprise Value
- $27.42B
- EPS (TTM)
- $2.31
- PE Ratio
- 29.85
- PEG Ratio
- 0.71
- Total Revenue (TTM)
- $4.82B
- Gross Profit (TTM)
- $2.96B
- EBITDA (TTM)
- $1.37B
- Year Range
- $54.11 - $89.98
- Target Price
- $85.00
- ROA (TTM)
- 14.03%
- ROE (TTM)
- 31.47%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DXCM Performance Chart
DexCom, Inc. (DXCM) is up 4.1% since the beginning of the year. At $69 per share, DXCM is trading 23.2% below its 52-week high of $90. Investors who bought $1,000 worth of DXCM shares 5 years ago would now be looking at an investment worth $640.
Loading charts...
Returns By Period
DexCom, Inc. (DXCM) has returned 4.07% so far this year and -13.66% over the past 12 months. Over the last ten years, DXCM has had an annualized return of 13.56%, just under the S&P 500 Index benchmark’s 13.88%.
DexCom, Inc.
- 1D
- -4.69%
- 1M
- -4.20%
- YTD
- 4.07%
- 6M
- 2.43%
- 1Y
- -13.66%
- 3Y*
- -18.32%
- 5Y*
- -8.54%
- 10Y*
- 13.56%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
DXCM Monthly Returns History
Based on dividend-adjusted daily data since Apr 14, 2005, DXCM's average daily return is +0.12%, while the average monthly return is +2.44%. At this rate, an investment would double in approximately 2.4 years.
Historically, 55% of months were positive and 45% were negative. The best month was Apr 2008 with a return of +86.0%, while the worst month was Nov 2008 at -55.8%. The longest winning streak lasted 11 consecutive months, and the longest losing streak was 7 months.
On a daily basis, DXCM closed higher 51% of trading days. The best single day was Dec 4, 2008 with a return of +50.3%, while the worst single day was Jul 26, 2024 at -40.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 10.05% | 0.53% | -14.48% | -5.18% | 23.83% | -6.33% | 4.07% | ||||||
| 2025 | 11.65% | 1.77% | -22.72% | 4.52% | 20.20% | 1.74% | -7.47% | -6.72% | -10.68% | -13.48% | 9.02% | 4.57% | -14.66% |
| 2024 | -2.21% | -5.18% | 20.54% | -8.15% | -6.77% | -4.54% | -40.18% | 2.24% | -3.32% | 5.13% | 10.66% | -0.28% | -37.33% |
| 2023 | -5.43% | 3.66% | 4.66% | 4.44% | -3.36% | 9.59% | -3.07% | -18.93% | -7.61% | -4.79% | 30.05% | 7.42% | 9.58% |
| 2022 | -19.83% | -3.85% | 23.60% | -20.14% | -27.08% | 0.06% | 10.13% | 0.16% | -2.03% | 49.96% | -3.73% | -2.61% | -15.64% |
| 2021 | 1.39% | 6.12% | -9.65% | 7.43% | -4.33% | 15.60% | 20.73% | 2.70% | 3.29% | 13.96% | -9.73% | -4.56% | 45.23% |
Benchmark Metrics
DexCom, Inc. has an annualized alpha of 19.07%, beta of 1.15, and R2 of 0.16 versus S&P 500 Index. Calculated based on daily prices since April 14, 2005.
- This stock captured 136.70% of S&P 500 Index gains and 105.35% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.16 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.07%
- Beta
- 1.15
- R²
- 0.16
- Upside Capture
- 136.70%
- Downside Capture
- 105.35%
Return for Risk
Risk / Return Rank
DXCM ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for DexCom, Inc. (DXCM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DXCM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.36 | ||
| Sortino ratioReturn per unit of downside risk | -2.95 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.37 | -0.40 |
| Calmar ratioReturn relative to maximum drawdown | -0.35 | 2.78 | -3.14 |
| Martin ratioReturn relative to average drawdown | -0.60 | 12.44 | -13.04 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the DexCom, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the DexCom, Inc. was 94.61%, occurring on Nov 20, 2008. Recovery took 1185 trading sessions.
The current DexCom, Inc. drawdown is 57.58%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Financial crisis2007–2009 | -94.61%Nov 2008 | 2y 6mo | 4y 8mo | 7y 3moMay 2006 - Aug 2013 |
2025 bear market2025 | -66.32%Nov 2025 | 3y 11mo | — | 4y 7moNov 2021 - now |
2017 bear market2017 | -56.37%Oct 2017 | 2y 1mo | 8mo 18d | 2y 9moSep 2015 - Jul 2018 |
2014 bear market2014 | -39.59%May 2014 | 2mo 2d | 6mo 4d | 8mo 6dMar 2014 - Nov 2014 |
COVID crash2020 | -36.81%Mar 2020 | 26d | 29d | 1mo 25dFeb 2020 - Apr 2020 |
Drawdown Indicators
| DXCM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.61% | -56.78% | -37.83% |
Max Drawdown (1Y)Largest decline over 1 year | -38.75% | -9.10% | -29.65% |
Max Drawdown (3Y)Largest decline over 3 years | -60.95% | -18.90% | -42.05% |
Max Drawdown (5Y)Largest decline over 5 years | -66.32% | -25.43% | -40.89% |
Max Drawdown (10Y)Largest decline over 10 years | -66.32% | -33.92% | -32.40% |
Current DrawdownCurrent decline from peak | -57.58% | -1.80% | -55.78% |
Average DrawdownAverage peak-to-trough decline | -36.04% | -10.71% | -25.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.94% | 2.03% | +20.91% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of DexCom, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how DexCom, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for DXCM, comparing it with other companies in the Diagnostics & Research industry. Currently, DXCM has a P/E ratio of 29.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for DXCM compared to other companies in the Diagnostics & Research industry. DXCM currently has a PEG ratio of 0.7. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DXCM relative to other companies in the Diagnostics & Research industry. Currently, DXCM has a P/S ratio of 5.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DXCM in comparison with other companies in the Diagnostics & Research industry. Currently, DXCM has a P/B value of 9.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DXCM
Add DexCom, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DXCM